| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pre-Eclampsia | 6 | 2022 | 231 | 0.890 |
Why?
|
| Infant, Premature | 7 | 2022 | 843 | 0.600 |
Why?
|
| Blood-Brain Barrier | 4 | 2019 | 156 | 0.470 |
Why?
|
| Infant, Very Low Birth Weight | 4 | 2006 | 176 | 0.470 |
Why?
|
| Fetal Blood | 2 | 2014 | 172 | 0.440 |
Why?
|
| Neonatal Screening | 3 | 2011 | 192 | 0.380 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2015 | 248 | 0.380 |
Why?
|
| Sepsis | 2 | 2011 | 516 | 0.350 |
Why?
|
| Streptococcus agalactiae | 1 | 2011 | 103 | 0.340 |
Why?
|
| Infant, Newborn | 19 | 2022 | 8548 | 0.310 |
Why?
|
| Streptococcal Infections | 1 | 2011 | 248 | 0.300 |
Why?
|
| Cocaine | 3 | 1995 | 214 | 0.290 |
Why?
|
| Pregnancy Complications | 3 | 2019 | 551 | 0.260 |
Why?
|
| Influenza Vaccines | 2 | 2023 | 498 | 0.260 |
Why?
|
| Emollients | 1 | 2006 | 2 | 0.250 |
Why?
|
| Spinal Puncture | 2 | 1996 | 52 | 0.240 |
Why?
|
| Protein Kinases | 1 | 2007 | 331 | 0.240 |
Why?
|
| Water-Electrolyte Balance | 1 | 2006 | 83 | 0.240 |
Why?
|
| Pregnancy | 16 | 2022 | 7557 | 0.240 |
Why?
|
| Sirolimus | 1 | 2007 | 241 | 0.230 |
Why?
|
| Syphilis, Congenital | 2 | 1996 | 30 | 0.230 |
Why?
|
| Influenza, Human | 2 | 2023 | 700 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 502 | 0.220 |
Why?
|
| Pericardiocentesis | 1 | 2004 | 17 | 0.220 |
Why?
|
| Infant Mortality | 2 | 1995 | 179 | 0.220 |
Why?
|
| Trophoblasts | 2 | 2015 | 118 | 0.210 |
Why?
|
| Endothelial Cells | 2 | 2019 | 526 | 0.200 |
Why?
|
| Catheterization, Central Venous | 1 | 2004 | 140 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 816 | 0.190 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 1995 | 240 | 0.190 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2023 | 189 | 0.180 |
Why?
|
| Case-Control Studies | 5 | 2023 | 3414 | 0.170 |
Why?
|
| Thyroxine | 1 | 2000 | 65 | 0.160 |
Why?
|
| Erythrocyte Transfusion | 1 | 2001 | 138 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 1348 | 0.160 |
Why?
|
| Substance-Related Disorders | 2 | 1995 | 491 | 0.160 |
Why?
|
| Fetal Growth Retardation | 3 | 2022 | 254 | 0.160 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2022 | 211 | 0.160 |
Why?
|
| Diabetes, Gestational | 2 | 2017 | 114 | 0.150 |
Why?
|
| Hydrogen Peroxide | 1 | 2019 | 124 | 0.140 |
Why?
|
| Pregnancy Trimester, First | 2 | 2015 | 124 | 0.140 |
Why?
|
| Humans | 32 | 2023 | 132236 | 0.130 |
Why?
|
| Database Management Systems | 1 | 2017 | 30 | 0.130 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 2 | 1996 | 83 | 0.130 |
Why?
|
| Infant, Premature, Diseases | 3 | 2011 | 252 | 0.130 |
Why?
|
| Infant, Low Birth Weight | 2 | 1995 | 174 | 0.130 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 72 | 0.130 |
Why?
|
| Calpain | 1 | 2016 | 43 | 0.130 |
Why?
|
| Gestational Age | 4 | 2022 | 1227 | 0.130 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2015 | 253 | 0.120 |
Why?
|
| Female | 21 | 2022 | 70778 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 84 | 0.120 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2015 | 496 | 0.120 |
Why?
|
| Melatonin | 1 | 2016 | 30 | 0.120 |
Why?
|
| Toll-Like Receptors | 1 | 2016 | 84 | 0.120 |
Why?
|
| Syphilis Serodiagnosis | 1 | 1995 | 15 | 0.120 |
Why?
|
| Meningitis | 1 | 1996 | 100 | 0.120 |
Why?
|
| Chemokines | 1 | 2016 | 130 | 0.120 |
Why?
|
| Protease Inhibitors | 1 | 2016 | 97 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2016 | 137 | 0.120 |
Why?
|
| Quinazolines | 1 | 2016 | 187 | 0.120 |
Why?
|
| Hormones | 1 | 2016 | 170 | 0.120 |
Why?
|
| Postnatal Care | 1 | 1995 | 52 | 0.120 |
Why?
|
| Cyclic GMP-Dependent Protein Kinase Type I | 1 | 2015 | 18 | 0.110 |
Why?
|
| Renin | 1 | 2015 | 95 | 0.110 |
Why?
|
| Metabolomics | 1 | 2019 | 480 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 169 | 0.110 |
Why?
|
| Herpes Simplex | 1 | 2015 | 56 | 0.110 |
Why?
|
| Cyclic GMP | 1 | 2015 | 95 | 0.110 |
Why?
|
| Receptors, Artificial | 1 | 2014 | 1 | 0.110 |
Why?
|
| Syphilis | 1 | 1995 | 98 | 0.110 |
Why?
|
| Thiourea | 1 | 2014 | 10 | 0.110 |
Why?
|
| Incidence | 3 | 2022 | 3377 | 0.110 |
Why?
|
| Proteomics | 1 | 2019 | 596 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 2681 | 0.110 |
Why?
|
| Glycoproteins | 1 | 2016 | 376 | 0.110 |
Why?
|
| Capillary Permeability | 1 | 2014 | 74 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2014 | 140 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 486 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 589 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2022 | 17394 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2016 | 418 | 0.100 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1995 | 180 | 0.100 |
Why?
|
| Rats | 5 | 2019 | 3607 | 0.100 |
Why?
|
| Tobacco Use Disorder | 1 | 1993 | 87 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2015 | 235 | 0.100 |
Why?
|
| Glucose | 2 | 2015 | 871 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2015 | 679 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 451 | 0.100 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2016 | 302 | 0.100 |
Why?
|
| Birth Weight | 3 | 2022 | 351 | 0.100 |
Why?
|
| Delivery, Obstetric | 1 | 1995 | 264 | 0.100 |
Why?
|
| Blood Cell Count | 1 | 2011 | 68 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 234 | 0.090 |
Why?
|
| Craniosynostoses | 1 | 1993 | 130 | 0.090 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2022 | 337 | 0.090 |
Why?
|
| Urine | 1 | 1991 | 91 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 516 | 0.080 |
Why?
|
| Cells, Cultured | 4 | 2019 | 3046 | 0.080 |
Why?
|
| Specimen Handling | 1 | 1991 | 151 | 0.080 |
Why?
|
| Seasons | 2 | 2023 | 328 | 0.080 |
Why?
|
| Adult | 8 | 2022 | 31622 | 0.080 |
Why?
|
| Risk Factors | 4 | 2022 | 10948 | 0.080 |
Why?
|
| Flow Cytometry | 2 | 2014 | 802 | 0.080 |
Why?
|
| Inflammation | 1 | 2016 | 1520 | 0.070 |
Why?
|
| Male | 10 | 2022 | 65006 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 3017 | 0.070 |
Why?
|
| Everolimus | 1 | 2007 | 50 | 0.070 |
Why?
|
| Aromatase Inhibitors | 1 | 2007 | 78 | 0.070 |
Why?
|
| Young Adult | 3 | 2015 | 9966 | 0.060 |
Why?
|
| Nitriles | 1 | 2007 | 155 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 2140 | 0.060 |
Why?
|
| Vaccination | 2 | 2023 | 1018 | 0.060 |
Why?
|
| Triazoles | 1 | 2007 | 147 | 0.060 |
Why?
|
| Hospitalization | 1 | 1995 | 1902 | 0.060 |
Why?
|
| Interleukin-1beta | 2 | 2016 | 163 | 0.060 |
Why?
|
| Administration, Topical | 1 | 2006 | 140 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 265 | 0.060 |
Why?
|
| District of Columbia | 2 | 1995 | 17 | 0.060 |
Why?
|
| Intestinal Atresia | 1 | 2005 | 20 | 0.060 |
Why?
|
| Hirschsprung Disease | 1 | 2005 | 38 | 0.060 |
Why?
|
| Bilirubin | 1 | 2006 | 128 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 1080 | 0.060 |
Why?
|
| Ileum | 1 | 2005 | 130 | 0.060 |
Why?
|
| Estradiol | 1 | 2007 | 488 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2007 | 446 | 0.060 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2004 | 13 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2014 | 6572 | 0.050 |
Why?
|
| Silicones | 1 | 2004 | 33 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1671 | 0.050 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2004 | 111 | 0.050 |
Why?
|
| Pericardial Effusion | 1 | 2004 | 72 | 0.050 |
Why?
|
| Infant | 4 | 2023 | 13048 | 0.050 |
Why?
|
| Influenza B virus | 1 | 2023 | 100 | 0.050 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2023 | 123 | 0.050 |
Why?
|
| Pregnancy Outcome | 2 | 2016 | 635 | 0.050 |
Why?
|
| Vaccines, Inactivated | 1 | 2023 | 148 | 0.050 |
Why?
|
| Prenatal Care | 2 | 1995 | 359 | 0.050 |
Why?
|
| Neoplasms | 1 | 2016 | 2961 | 0.040 |
Why?
|
| Deficiency Diseases | 1 | 2000 | 9 | 0.040 |
Why?
|
| Vaccination Coverage | 1 | 2021 | 37 | 0.040 |
Why?
|
| Thyroid Diseases | 1 | 2000 | 29 | 0.040 |
Why?
|
| Apoptosis | 1 | 2007 | 1901 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2007 | 2511 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 3691 | 0.040 |
Why?
|
| Cell Line | 2 | 2015 | 2724 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2022 | 417 | 0.040 |
Why?
|
| Tight Junctions | 1 | 2019 | 40 | 0.040 |
Why?
|
| Outpatients | 1 | 2021 | 275 | 0.040 |
Why?
|
| Permeability | 1 | 2019 | 117 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2021 | 416 | 0.040 |
Why?
|
| Animals | 5 | 2019 | 34842 | 0.040 |
Why?
|
| Logistic Models | 1 | 2022 | 1842 | 0.030 |
Why?
|
| Systole | 1 | 2017 | 205 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 257 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 181 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 4758 | 0.030 |
Why?
|
| Aminophylline | 1 | 1996 | 8 | 0.030 |
Why?
|
| Cell Survival | 1 | 2019 | 868 | 0.030 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 1996 | 22 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 162 | 0.030 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 1996 | 73 | 0.030 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2015 | 7 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1996 | 249 | 0.030 |
Why?
|
| Guanylate Cyclase | 1 | 2015 | 35 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2016 | 203 | 0.030 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 1995 | 20 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 1996 | 136 | 0.030 |
Why?
|
| Intensive Care, Neonatal | 1 | 1995 | 57 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 398 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 1996 | 150 | 0.030 |
Why?
|
| Hypothermia | 1 | 1995 | 66 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 5412 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 81 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 689 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2014 | 50 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2014 | 46 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 3093 | 0.030 |
Why?
|
| CD4 Antigens | 1 | 2014 | 56 | 0.030 |
Why?
|
| Patient Admission | 1 | 1995 | 187 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 101 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2014 | 39 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 56 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2014 | 92 | 0.030 |
Why?
|
| Imidazoles | 1 | 2015 | 219 | 0.030 |
Why?
|
| Adolescent | 3 | 2021 | 20559 | 0.030 |
Why?
|
| Brain Edema | 1 | 2014 | 70 | 0.030 |
Why?
|
| Pyridines | 1 | 2015 | 249 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2016 | 413 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 5173 | 0.020 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2015 | 325 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 1363 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2015 | 4720 | 0.020 |
Why?
|
| Odds Ratio | 1 | 1995 | 1257 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 880 | 0.020 |
Why?
|
| Research Design | 1 | 1996 | 743 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 444 | 0.020 |
Why?
|
| Premature Birth | 1 | 2016 | 418 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 387 | 0.020 |
Why?
|
| Infant Care | 1 | 1991 | 47 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1714 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 2015 | 461 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 1224 | 0.020 |
Why?
|
| Placenta | 1 | 2015 | 539 | 0.020 |
Why?
|
| Fetus | 1 | 1993 | 590 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 1996 | 2314 | 0.020 |
Why?
|
| Reference Values | 1 | 1991 | 703 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 7128 | 0.020 |
Why?
|
| Mice | 2 | 2016 | 18504 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 3763 | 0.020 |
Why?
|
| Prevalence | 1 | 1995 | 2665 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 1338 | 0.020 |
Why?
|
| Child | 2 | 2023 | 25783 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2023 | 14735 | 0.020 |
Why?
|
| United States | 1 | 2021 | 11688 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2000 | 13034 | 0.010 |
Why?
|
| Obesity | 1 | 2016 | 2399 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4690 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 21471 | 0.010 |
Why?
|
| Theophylline | 1 | 1996 | 24 | 0.010 |
Why?
|
| Apnea | 1 | 1996 | 31 | 0.010 |
Why?
|
| Middle Aged | 1 | 2016 | 29032 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1996 | 996 | 0.010 |
Why?
|